Treatment for glioblastoma
AssigneeHadasit Medical Research Services and Development Ltd.
InventorsIris LAVON BEN MOSHE, Tamar CANELLO AVRAMOVITCH
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.
Claims27
1-62. (canceled)
A method for treating a neuroepithelial tumor in a subject in need thereof, comprising administering to the subject enzalutamide or derivative thereof in a therapeutically effective amount, wherein the tumor is characterized by androgen receptor (AR) expression in at least a portion of the tumor cells.
A method of treating a brain tumor characterized by AR expression in at least a portion of the tumor cells in a subject in need thereof, comprising administering to the subject a therapeutic combination of at least one AR antagonist or inhibitor and at least one anti-cancer agent selected from the group consisting of an alkylating agent and a receptor tyrosine kinase (RTK) inhibitor.
A method of determining if a subject afflicted with a brain tumor is amenable for treatment with an AR antagonist or inhibitor, comprising determining the presence of at least one AR aberration selected from the group consisting of:
- amplification at the AR gene locus, LOH at the AR gene locus, AR over-expression and expression of at least one AR variant, in a sample of the subject, wherein the presence of the at least one aberration indicates that said subject is amenable for treatment with the AR antagonist or inhibitor.
A kit comprising a combination of at least one AR antagonist or inhibitor and at least one anti-cancer agent selected from the group consisting of an alkylating agent and a RTK inhibitor, further comprising instructions for administering said combination to a subject afflicted with an AR-expressing neuroepithelial tumor.
Dependencies are inferred from the claim text.